Evidence map›Paper›PMID 24665449›Full record

ReviewSouth Asian journal of cancer2014

Eribulin drug review.

Nishitha Shetty, Sudeep Gupta

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in South Asian journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 53 citations in OpenAlex.

  1. Trial
  2. Modern synthetic pathways towards eribulin and its subunits.Beilstein journal of organic chemistry · 2026
    Review
  3. Review
  4. Article
  5. Cardio-Oncology and Breast Cancer Therapies.Current treatment options in oncology · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Novel molecules as the emerging trends in cancer treatment: an update.Medical oncology (Northwood, London, England) · 2022
    Review
  15. Review
  16. Efficacy of Eribulin in Soft Tissue Sarcomas.Frontiers in pharmacology · 2022
    Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nishitha ShettyDepartment of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Sudeep GuptaDepartment of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Tata Memorial Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage. In patients with metastatic breast cancer refractory to anthracyclines and taxanes, eribulin is one of the life-saving options. Neutropenia, neuropathy and QT prolongation are the most frequent adverse events associated with this drug. Phase I/II trials are also underway in refractory lung, ovarian, pancreatic, bladder, and soft tissue tumors. Larger prospective studies will define the role of this drug in a wide variety of tumors, and the future looks very promising.

Indexed as

breast chemotherapyEribulintaxane

Identifiers

PMID24665449
PMCPMC3961871
OpenAlexW2017697710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.